FLT3 internal tandem duplication associates with adverse outcome and gene- and microRNA-expression signatures in patients 60 years of age or older with primary cytogenetically normal acute myeloid leukemia: a Cancer and Leukemia Group B study.

Blood
Susan P WhitmanClara D Bloomfield

Abstract

The clinical impact of FLT3-internal tandem duplications (ITDs), an adverse prognostic marker in adults aged < 60 years with primary cytogenetically normal acute myeloid leukemia (CN-AML), requires further investigation in older patients. In CN-AML patients aged ≥ 60 years treated on Cancer and Leukemia Group B frontline trials, we found that FLT3-ITD remained associated with shorter disease-free survival (P < .001; hazard ratio = 2.10) and overall survival (P < .001; hazard ratio = 1.97) in multivariable analyses. This impact on shorter disease-free survival and overall survival was in patients aged 60-69 (P < .001, each) rather than in those aged ≥ 70 years. An FLT3-ITD-associated gene-expression signature revealed overexpression of FLT3, homeobox genes (MEIS1, PBX3, HOXB3), and immunotherapeutic tar-gets (WT1, CD33) and underexpression of leukemia-associated (MLLT3, TAL1) and erythropoiesis-associated (GATA3, EPOR, ANK1, HEMGN) genes. An FLT3-ITD-associated microRNA-expression signature included overexpressed miR-155 and underexpressed miR-144 and miR-451. FLT3-ITD identifies older CN-AML patients with molecular high risk and is associated with gene- and microRNA-expression signatures that provide biologic insights for novel...Continue Reading

References

Jan 19, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Claudia D BaldusGerhard Ehninger
Mar 21, 2007·Proceedings of the National Academy of Sciences of the United States of America·R Mehrian-ShaiC L Sawyers
May 3, 2008·The New England Journal of Medicine·Guido MarcucciClara D Bloomfield
Jun 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Peter PaschkaClara D Bloomfield
Jun 30, 2009·American Journal of Hematology·Felicetto FerraraFabrizio Pane
Aug 7, 2009·The New England Journal of Medicine·Elaine R MardisTimothy J Ley
Mar 20, 2010·Journal of Cancer Education : the Official Journal of the American Association for Cancer Education·Ian C Hoppe
Apr 7, 2010·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield

❮ Previous
Next ❯

Citations

Sep 9, 2011·Current Treatment Options in Oncology·Gabriela Motyckova, Richard M Stone
Jun 13, 2012·International Journal of Hematology·Liang HuangJianfeng Zhou
Jul 14, 2012·International Journal of Hematology·Masamitsu Yanada, Tomoki Naoe
Jun 27, 2013·Proceedings of the National Academy of Sciences of the United States of America·Ping ChenJianjun Chen
Apr 6, 2011·The Journal of Experimental Medicine·Xiaoyu LiHarald von Boehmer
Dec 22, 2012·Leukemia Research and Treatment·Yao YuanElizabeth Raveche
Nov 4, 2010·Blood·Guido MarcucciClara D Bloomfield
Feb 24, 2011·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Klaus H MetzelerClara D Bloomfield
Feb 1, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Guido MarcucciClara D Bloomfield
Dec 12, 2012·PloS One·Fatemat HassanEstelle Cormet-Boyaka
Aug 25, 2011·Drugs·Luis Villela, Javier Bolaños-Meade
May 23, 2014·Clinical Interventions in Aging·Ming Y Lim, Katarzyna Jamieson
Feb 25, 2014·Future Oncology·Etienne De BraekeleerMarc De Braekeleer
May 20, 2014·Current Hematologic Malignancy Reports·James M Foran
Mar 16, 2013·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Xiaomeng HuangGuido Marcucci
Nov 10, 2015·Biology of Blood and Marrow Transplantation : Journal of the American Society for Blood and Marrow Transplantation·A D HoUNKNOWN Study Alliance Leukemia (SAL)
Mar 5, 2014·Expert Opinion on Drug Safety·Shuang ZhangYuquan Wei
Mar 23, 2011·Expert Opinion on Emerging Drugs·Hillary PrescottFarhad Ravandi
Jan 15, 2015·Molecular Medicine Reports·Ewa MusialikJanusz Aleksander Siedlecki
Dec 17, 2014·Proceedings of the National Academy of Sciences of the United States of America·Ramiro GarzonClara D Bloomfield
Oct 5, 2014·Journal of Hematology & Oncology·Sanam LoghaviJoseph D Khoury
Jan 20, 2016·International Journal of Hematology·Masamitsu YanadaNobuhiko Emi
Oct 8, 2011·Cellular Signalling·Megan Y MurrayDavid J MacEwan
Jun 24, 2011·Leukemia Research·Harshabad SinghEyal C Attar
Mar 23, 2011·Seminars in Oncology·Lucy A GodleyMichelle M Le Beau
Nov 28, 2015·Briefings in Functional Genomics·Norma I Rodríguez-Malavé, Dinesh S Rao
Jul 15, 2015·Asian Pacific Journal of Cancer Prevention : APJCP·Noraini Mat YunusRosline Hassan
May 18, 2013·British Journal of Haematology·Jane E A GordonJohn E J Rasko

❮ Previous
Next ❯

Related Concepts

Related Feeds

Blood And Marrow Transplantation

The use of hematopoietic stem cell transplantation or blood and marrow transplantation (bmt) is on the increase worldwide. BMT is used to replace damaged or destroyed bone marrow with healthy bone marrow stem cells. Here is the latest research on bone and marrow transplantation.

AML: Role of LSD1 by CRISPR (Keystone)

Find the latest rersearrch on the ability of CRISPR-Cas9 mutagenesis to profile the interactions between lysine-specific histone demethylase 1 (LSD1) and chemical inhibitors in the context of acute myeloid leukemia (AML) here.

Acute Myeloid Leukemia

Acute myeloid leukemia (AML) is a clinically and genetically heterogeneous disease with approximately 20,000 cases per year in the United States. AML also accounts for 15-20% of all childhood acute leukemias, while it is responsible for more than half of the leukemic deaths in these patients. Here is the latest research on this disease.